Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lian Cardiovascular
Shanghai, Shanghai, Chinalianbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lian Cardiovascular is a specialized therapeutic division of LianBio, focused on developing and commercializing innovative cardiovascular therapies for the Greater China market and other Asian territories. The company's lead program is mavacamten, a first-in-class cardiac myosin inhibitor licensed from Bristol Myers Squibb (formerly MyoKardia) for the treatment of hypertrophic cardiomyopathy. Lian Cardiovascular leverages a cross-border model to bridge global biopharmaceutical innovation with the significant unmet medical needs in China. Its pipeline also includes danicamtiv, a cardiac myosin activator aimed at treating heart failure with reduced ejection fraction.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Bristol Myers SquibbMyoKardia
Beyond the preview
Go deeper on Lian Cardiovascular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lian Cardiovascular.